Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > June presentation

<< Previous

Bullboard Posts

Next >>

Comment by biorunon Jun 02, 2021 3:25pm

163 Views

Post# 33312428

RE:RE:June presentation

I found the may presentation. Looks like Tenibrother was right. Same information but why underline now in a such a discrete way?

If you look on this slide, they clearly went out of their way to underline the embedded target on this slide:

Wanbang Biopharmaceuticals Agreement (2014)

In January 2014, Sirona signed a license agreement with Wanbang Biopharmaceuticals (Wanbang), a subsidiary of Fosun Pharmaceutical Group, which is listed on the Hong Kong stock exchange
The license allows Wanbang to develop and commercialize Sirona’s anti-diabetic SGLT2 inhibitor, TFC- 039, exclusively in the People’s Republic of China (PRC)
In return for the license, Wanbang provides upfront and milestone payments of up to US$9.5M in addition to royalty payments for product sales in the PRC
To date, Sirona has received $1.5 M in milestone payments
TFC-039 is currently in multiple Phase I clinical trials and expected to complete in the first half of 2021 (this sentenced is underlined in the June presentation)
China diabetes market reached a value of US$ 3.8 Billion in 2019, growing at a CAGR of around 11% during 2014-2019 (https://www.imarcgroup.com/china-diabetes-market)